Terry Lichtor

Rush University Medical Center United States of America

Terry Lichtor, MD, Ph.D., is a practicing neurosurgeon. He has several research interests, and his brain tumor work is largely focused on the development of a DNA vaccine for the treatment of primary and metastatic intracerebral tumors. Dr. Lichtor has shown that vaccines prepared by the transfer of DNA from the tumor into a highly immunogenic cell line can encompass the array of tumor antigens that characterize the patient population. Poorly immunogenic tumor antigens, characteristic of malignant cells, can become strongly antigenic if they are expressed by highly immunogenic cells. The introduction of the vaccine directly into the tumor bed of animals with an intracerebral tumor stimulates a systemic cellular anti-tumor immune response associated with a prolongation of survival. Hopefully, this vaccine strategy will be efficacious in the treatment of patients with brain tumors. Dr. Lichtor is a member of the American College of Surgeons and the neurosurgery faculty at Rush University Medical Center, Chicago, Illinois, USA.

Terry Lichtor

3books edited

3chapters authored

Latest work with IntechOpen by Terry Lichtor

A dramatic increase in knowledge regarding the molecular biology of gliomas has been established over the past few years, and this has led to the development of novel therapeutic strategies for these patients. This book describes some improvements in the surgical management of gliomas, including segmentation of brain MRI images using 4D MRI volumes to help with the diagnosis and monitoring of patients. Another novel topic reviewed involves the applications of photosensitizers and their efficacy in the generation of anti-tumor responses in photodynamic therapy. A review of the application of nanoparticles and their ability to deliver drugs to the tumor site with a reduction in systemic toxicity is another developing therapy discussed. The book also describes novel approaches involving the development of the use of microRNAs, which are non-coding RNAs that can be used as tumor suppressors that potentially can be developed to control the growth of gliomas. The book examines a large number of molecular interactions of signals in gliomas, which should lead to biomarkers of potential importance that could be manipulated in the development of clinical trials. Molecular networks need to be better understood for the development of therapeutic strategies. Finally, the book reviews immunotherapeutic strategies potentially useful in treating brain tumors that involve either poxviruses engineered to secrete IL-15- or IL-2-secreting fibroblasts transfected with tumor DNA. The stimulation of the immune system to selectively attack malignant cells should lead to the prolongation of survival of brain tumor patients without a decline in cognitive functions or other side effects. It is hoped that this new information will lead to improved and efficacious treatment strategies for these challenging tumors.

Go to the book
Molecular Biology and Treatment Strategies for Gliomas IntechOpen
Molecular Biology and Treatment Strateg... Edited by Terry Lichtor

Molecular Biology and Treatment Strategies for Gliomas

Edited by Terry Lichtor